A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients
with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to
assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered
dose (MAD) for MTD is not reached of GNC-039.